tradingkey.logo

CVRx Inc

CVRX
6.550USD
-0.090-1.36%
終値 02/06, 16:00ET15分遅れの株価
171.57M時価総額
損失額直近12ヶ月PER

CVRx Inc

6.550
-0.090-1.36%

詳細情報 CVRx Inc 企業名

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

CVRx Incの企業情報

企業コードCVRX
会社名CVRx Inc
上場日Jun 30, 2021
最高経営責任者「CEO」Hykes (Kevin)
従業員数206
証券種類Ordinary Share
決算期末Jun 30
本社所在地9201 West Broadway Avenue
都市MINNEAPOLIS
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号55445
電話番号17634162850
ウェブサイトhttps://www.cvrx.com/
企業コードCVRX
上場日Jun 30, 2021
最高経営責任者「CEO」Hykes (Kevin)

CVRx Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+5000.00%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+16000.00%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
+16600.00%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-22000.00%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kirk Nielsen
Mr. Kirk Nielsen
Independent Director
Independent Director
--
--
Dr. Philip B. Adamson
Dr. Philip B. Adamson
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert John
Mr. Robert John
Chief Revenue Officer
Chief Revenue Officer
--
-55000.00%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+5000.00%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+16000.00%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
+16600.00%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-22000.00%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--

収益内訳

通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
US
13.49M
91.85%
Others
1.20M
8.15%
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
Johnson & Johnson Innovation-JJDC, Inc.
15.36%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.28%
他の
61.42%
株主統計
株主統計
比率
Johnson & Johnson Innovation-JJDC, Inc.
15.36%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.28%
他の
61.42%
種類
株主統計
比率
Venture Capital
29.62%
Investment Advisor
10.99%
Hedge Fund
9.14%
Investment Advisor/Hedge Fund
5.96%
Private Equity
4.69%
Individual Investor
4.32%
Research Firm
3.62%
Pension Fund
0.42%
Bank and Trust
0.14%
他の
31.09%

機関投資家保有株

更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
228
17.05M
80.90%
-52.59K
2025Q3
232
17.10M
82.20%
-620.32K
2025Q2
227
17.72M
82.14%
-1.50M
2025Q1
219
19.22M
81.40%
-1.99M
2024Q4
217
18.52M
88.19%
+738.46K
2024Q3
205
17.48M
85.56%
+1.01M
2024Q2
202
16.95M
94.67%
-325.79K
2024Q1
200
17.25M
89.54%
-2.08M
2023Q4
194
16.01M
92.75%
+1.64M
2023Q3
187
14.37M
98.58%
+302.86K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Johnson & Johnson Innovation-JJDC, Inc.
4.04M
15.42%
-61.57K
-1.50%
Nov 26, 2025
New Enterprise Associates (NEA)
2.03M
7.73%
--
--
Sep 30, 2025
Vensana Capital Management LLC
1.71M
6.53%
--
--
Dec 31, 2024
Gilde Equity Management Benelux B.V.
1.23M
4.69%
-136.72K
-10.01%
Feb 04, 2025
The Vanguard Group, Inc.
1.09M
4.16%
+12.95K
+1.20%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
939.45K
3.58%
-9.60K
-1.01%
Sep 30, 2025
Jain (Mudit Kumar)
938.43K
3.58%
+1.65K
+0.18%
May 13, 2025
Balyasny Asset Management LP
696.26K
2.66%
+21.57K
+3.20%
Sep 30, 2025
Parkman Healthcare Partners LLC
491.41K
1.87%
-297.69K
-37.73%
Sep 30, 2025
Morgan Stanley & Co. LLC
406.22K
1.55%
+58.56K
+16.84%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
JPMorgan Fundamental Data Science Small Core ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
詳細を見る
iShares Micro-Cap ETF
比率0.03%
Proshares Ultra Russell 2000
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
iShares Russell 2000 Growth ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
JPMorgan Fundamental Data Science Small Core ETF
比率0%
iShares Russell 2000 Value ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI